Trial Review

Please note the ANZCTR website will be unavailable from 1-2 pm (AEST) on Thursday, the 19th of June for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00117676




Registration number
NCT00117676
Ethics application status
Date submitted
30/06/2005
Date registered
8/07/2005
Date last updated
7/03/2017

Titles & IDs
Public title
A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B
Scientific title
A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B
Secondary ID [1] 0 0
2004-005119-27
Secondary ID [2] 0 0
GS-US-174-0102
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Hepatitis B 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TDF
Treatment: Drugs - ADV
Treatment: Drugs - TDF placebo
Treatment: Drugs - ADV placebo
Treatment: Drugs - FTC/TDF

Experimental: TDF-TDF - TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.

Active comparator: ADV-TDF - ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.


Treatment: Drugs: TDF
300 mg tablet administered orally once daily

Treatment: Drugs: ADV
10 mg tablet administered orally once daily

Treatment: Drugs: TDF placebo
Tablet administered orally once daily

Treatment: Drugs: ADV placebo
Tablet administered orally once daily

Treatment: Drugs: FTC/TDF
200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48
Assessment method [1] 0 0
Complete response was a composite endpoint defined as histological response and HBV DNA \< 400 copies/mL. Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. A participant was a nonresponder for the primary endpoint if either biopsy (baseline or end-of-treatment) was missing or if there was not an HBV DNA value available at or beyond Week 40.
Timepoint [1] 0 0
Baseline; Week 48
Secondary outcome [1] 0 0
Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48
Assessment method [1] 0 0
Timepoint [1] 0 0
Week 48
Secondary outcome [2] 0 0
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 96
Assessment method [2] 0 0
Timepoint [2] 0 0
Week 96
Secondary outcome [3] 0 0
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384
Assessment method [3] 0 0
Timepoint [3] 0 0
Weeks 144, 192, 240, 288, 336, and 384
Secondary outcome [4] 0 0
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 432 and 480
Assessment method [4] 0 0
Timepoint [4] 0 0
Weeks 432 and 480
Secondary outcome [5] 0 0
Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
Assessment method [5] 0 0
Timepoint [5] 0 0
Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
Secondary outcome [6] 0 0
Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
Assessment method [6] 0 0
Timepoint [6] 0 0
Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
Secondary outcome [7] 0 0
Percentage of Participants With Histological Response at Week 48
Assessment method [7] 0 0
Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.
Timepoint [7] 0 0
Baseline; Week 48
Secondary outcome [8] 0 0
Percentage of Participants With Histological Response at Week 240
Assessment method [8] 0 0
Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.
Timepoint [8] 0 0
Baseline; Week 240
Secondary outcome [9] 0 0
Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48
Assessment method [9] 0 0
The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst).
Timepoint [9] 0 0
Baseline; Week 48
Secondary outcome [10] 0 0
Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240
Assessment method [10] 0 0
The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst).
Timepoint [10] 0 0
Baseline; Week 240
Secondary outcome [11] 0 0
Ranked Assessment of Necroinflammation and Fibrosis at Week 48
Assessment method [11] 0 0
Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening.
Timepoint [11] 0 0
Baseline; Week 48
Secondary outcome [12] 0 0
Ranked Assessment of Necroinflammation and Fibrosis at Week 240
Assessment method [12] 0 0
Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening.
Timepoint [12] 0 0
Baseline; Week 240
Secondary outcome [13] 0 0
Percentage of Participants With ALT Normalization at Week 48
Assessment method [13] 0 0
ALT normalization was defined as ALT \> upper limit of normal (ULN) at baseline and within the normal range at the end of blinded treatment. The ULN was 43 U/L for males and 34 U/L for females aged 18 to \< 69, and 35 U/L for males and 32 U/L for females aged = 69.
Timepoint [13] 0 0
Baseline; Week 48
Secondary outcome [14] 0 0
Percentage of Participants With ALT Normalization at Weeks 96
Assessment method [14] 0 0
ALT normalization was defined as ALT \> ULN at baseline and within the normal range at Week 96. The ULN was 43 U/L for males and 34 U/L for females aged 18 to \< 69, and 35 U/L for males and 32 U/L for females aged = 69.
Timepoint [14] 0 0
Baseline; Week 96
Secondary outcome [15] 0 0
Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384
Assessment method [15] 0 0
ALT normalization was defined as ALT \> ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to \< 69, and 35 U/L for males and 32 U/L for females aged = 69.
Timepoint [15] 0 0
Baseline; Weeks 144, 192, 240, 288, 336, and 384
Secondary outcome [16] 0 0
Percentage of Participants With ALT Normalization at Weeks 432 and 480
Assessment method [16] 0 0
ALT normalization was defined as ALT \> ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to \< 69, and 35 U/L for males and 32 U/L for females aged = 69.
Timepoint [16] 0 0
Baseline; Weeks 432 and 480
Secondary outcome [17] 0 0
Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
Assessment method [17] 0 0
Timepoint [17] 0 0
Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
Secondary outcome [18] 0 0
Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
Assessment method [18] 0 0
Timepoint [18] 0 0
Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
Secondary outcome [19] 0 0
Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion Antibody to HBs (Anti-HBs) at Week 48
Assessment method [19] 0 0
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 48.
Timepoint [19] 0 0
Baseline; Week 48
Secondary outcome [20] 0 0
Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Week 96
Assessment method [20] 0 0
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 96. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 96.
Timepoint [20] 0 0
Baseline; Week 96
Secondary outcome [21] 0 0
Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, 384, 432, and 480
Assessment method [21] 0 0
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point.
Timepoint [21] 0 0
Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480
Secondary outcome [22] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)
Assessment method [22] 0 0
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 48, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA = 400 copies/mL.
Timepoint [22] 0 0
Baseline; Week 48
Secondary outcome [23] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)
Assessment method [23] 0 0
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 96 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 48 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen and had HBV DNA = 400 copies/mL at the time of the addition.
Timepoint [23] 0 0
Baseline; Weeks 49 to 96
Secondary outcome [24] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)
Assessment method [24] 0 0
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 144 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 96 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 96 and had HBV DNA = 400 copies/mL at the time of the addition.
Timepoint [24] 0 0
Baseline; Weeks 97 to 144
Secondary outcome [25] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)
Assessment method [25] 0 0
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 192 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 144 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 144 and had HBV DNA = 400 copies/mL at the time of the addition.
Timepoint [25] 0 0
Baseline; Weeks 145 to 192
Secondary outcome [26] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)
Assessment method [26] 0 0
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 240 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 192 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 192 and had HBV DNA = 400 copies/mL at the time of the addition.
Timepoint [26] 0 0
Baseline; Weeks 193 to 240
Secondary outcome [27] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)
Assessment method [27] 0 0
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 288 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 240 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 240 and had HBV DNA = 400 copies/mL at the time of the addition.
Timepoint [27] 0 0
Baseline; Weeks 241 to 288
Secondary outcome [28] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)
Assessment method [28] 0 0
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 336 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 288 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 288 and had HBV DNA = 400 copies/mL at the time of the addition.
Timepoint [28] 0 0
Baseline; Weeks 289 to 336
Secondary outcome [29] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)
Assessment method [29] 0 0
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 384 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 336 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 336 and had HBV DNA = 400 copies/mL at the time of the addition.
Timepoint [29] 0 0
Baseline; Weeks 337 to 384
Secondary outcome [30] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 432 (Resistance Surveillance)
Assessment method [30] 0 0
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 432 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 384 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 384 and had HBV DNA = 400 copies/mL at the time of the addition.
Timepoint [30] 0 0
Baseline; Weeks 385 to 432
Secondary outcome [31] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 480 (Resistance Surveillance)
Assessment method [31] 0 0
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 480 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 432 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 432 and had HBV DNA = 400 copies/mL at the time of the addition.
Timepoint [31] 0 0
Baseline; Weeks 433 to 480

Eligibility
Key inclusion criteria
Key

* Chronic hepatitis B virus (HBV) infection, defined as positive serum hepatitis B s-antigen (HBsAg) for at least 6 months.
* 18 through 69 years of age, inclusive.
* Active hepatitis B e-antigen (HBeAg) negative chronic HBV infection, with all of the following:

* HBeAg negative and HBeAb positive at screening
* Alanine aminotransferase (ALT) levels > the upper limit of the normal range (ULN) and = 10 x ULN
* Serum HBV DNA > 100,000 copies/mL at screening
* Creatinine clearance = 70 mL/min
* Hemoglobin = 8 g/dL
* Neutrophils = 1,000 /mL
* Knodell necroinflammatory score = 3 and a Knodell fibrosis score < 4; however, up to 120 patients with cirrhosis, ie, a Knodell fibrosis score equal to 4, will be eligible for enrollment
* Negative serum ß-human chorionic gonadotropin (hCG)
* Nucleotide naive, ie, no prior nucleotide (TDF or ADV) therapy for greater than 12 weeks
* Nucleoside naive, ie, no prior nucleoside (any nucleoside) therapy for greater than 12 weeks. However, up to 120 patients with > 12 weeks prior lamivudine experience will be eligible
* Willing and able to provide written informed consent
* Had a liver biopsy performed within 6 months of baseline and has readable biopsy slides or agrees to have a biopsy performed prior to baseline

Key
Minimum age
18 Years
Maximum age
69 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Pregnant women, women who are breast feeding, or women who believe they may wish to become pregnant during the course of the study
* Males and females of reproductive potential who are unwilling to use an effective method of contraception during the study.
* Decompensated liver disease defined as conjugated bilirubin > 1.5 x ULN, prothrombin time (PT) > 1.5 x ULN, platelets < 75,000/mL, serum albumin < 3.0 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)
* Received any nucleoside, nucleotide (TDF or ADV) or interferon (pegylated or not) therapy within 6 months prior to the pre treatment biopsy
* Evidence of hepatocellular carcinoma (HCC)
* Coinfection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or hepatitis D virus (HDV)
* Significant renal, cardiovascular, pulmonary, or neurological disease
* Received solid organ or bone marrow transplantation
* Is currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion
* Has proximal tubulopathy

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/01/2016
Sample size
Target
Accrual to date
Final
382
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
- Camperdown
Recruitment hospital [2] 0 0
- Concord
Recruitment hospital [3] 0 0
- Westmead
Recruitment hospital [4] 0 0
- Woolloongabba
Recruitment hospital [5] 0 0
- Clayton
Recruitment hospital [6] 0 0
- Fitzroy
Recruitment hospital [7] 0 0
- Heidelberg
Recruitment hospital [8] 0 0
- Prahan
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
40102 - Woolloongabba
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3065 - Fitzroy
Recruitment postcode(s) [7] 0 0
3084 - Heidelberg
Recruitment postcode(s) [8] 0 0
3004 - Prahan
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
Hawaii
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Virginia
Country [9] 0 0
Bulgaria
State/province [9] 0 0
Sofia
Country [10] 0 0
Bulgaria
State/province [10] 0 0
Varna
Country [11] 0 0
Canada
State/province [11] 0 0
Alberta
Country [12] 0 0
Canada
State/province [12] 0 0
British Columbia
Country [13] 0 0
Canada
State/province [13] 0 0
Manitoba
Country [14] 0 0
Canada
State/province [14] 0 0
Ontario
Country [15] 0 0
Czech Republic
State/province [15] 0 0
Brno
Country [16] 0 0
Czech Republic
State/province [16] 0 0
Hradec Kralove
Country [17] 0 0
Czech Republic
State/province [17] 0 0
Praha 4
Country [18] 0 0
Czech Republic
State/province [18] 0 0
Praha 6 - Stresovice
Country [19] 0 0
France
State/province [19] 0 0
Clichy
Country [20] 0 0
France
State/province [20] 0 0
Creteil
Country [21] 0 0
France
State/province [21] 0 0
Lille
Country [22] 0 0
France
State/province [22] 0 0
Lyon
Country [23] 0 0
France
State/province [23] 0 0
Nancy
Country [24] 0 0
France
State/province [24] 0 0
Paris
Country [25] 0 0
France
State/province [25] 0 0
Strasbourg
Country [26] 0 0
France
State/province [26] 0 0
Toulouse
Country [27] 0 0
Germany
State/province [27] 0 0
Duesseldorf
Country [28] 0 0
Germany
State/province [28] 0 0
Frankfurt
Country [29] 0 0
Germany
State/province [29] 0 0
Hamburg
Country [30] 0 0
Germany
State/province [30] 0 0
Hannover
Country [31] 0 0
Germany
State/province [31] 0 0
Herne
Country [32] 0 0
Germany
State/province [32] 0 0
Homburg/Saar
Country [33] 0 0
Germany
State/province [33] 0 0
Mainz
Country [34] 0 0
Germany
State/province [34] 0 0
Munchen
Country [35] 0 0
Germany
State/province [35] 0 0
Tubingen
Country [36] 0 0
Greece
State/province [36] 0 0
Athens
Country [37] 0 0
Greece
State/province [37] 0 0
Larissa
Country [38] 0 0
Greece
State/province [38] 0 0
Leipzig
Country [39] 0 0
Greece
State/province [39] 0 0
Thessaloniki
Country [40] 0 0
Italy
State/province [40] 0 0
Bologna
Country [41] 0 0
Italy
State/province [41] 0 0
Torino
Country [42] 0 0
Netherlands
State/province [42] 0 0
Rotterdam
Country [43] 0 0
New Zealand
State/province [43] 0 0
Auckland
Country [44] 0 0
New Zealand
State/province [44] 0 0
Hamilton
Country [45] 0 0
New Zealand
State/province [45] 0 0
Whakatane
Country [46] 0 0
Poland
State/province [46] 0 0
Bialystok
Country [47] 0 0
Poland
State/province [47] 0 0
Bydgoszcz
Country [48] 0 0
Poland
State/province [48] 0 0
Chorzow
Country [49] 0 0
Poland
State/province [49] 0 0
Krakow
Country [50] 0 0
Poland
State/province [50] 0 0
Warszawa
Country [51] 0 0
Poland
State/province [51] 0 0
Wroclaw
Country [52] 0 0
Spain
State/province [52] 0 0
Madrid
Country [53] 0 0
Spain
State/province [53] 0 0
Barcelona
Country [54] 0 0
Spain
State/province [54] 0 0
Valencia
Country [55] 0 0
Turkey
State/province [55] 0 0
Bursa
Country [56] 0 0
Turkey
State/province [56] 0 0
Istanbul
Country [57] 0 0
Turkey
State/province [57] 0 0
Izmir
Country [58] 0 0
United Kingdom
State/province [58] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Gilead Sciences
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Gilead Study Director
Address 0 0
Gilead Sciences
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

TypeCitations or Other Details
Journal Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lamp... [More Details]
Journal Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, ... [More Details]
Journal Gordon SC, Krastev Z, Horban A, Petersen J, Sperl ... [More Details]
Journal Tsai NC, Marcellin P, Buti M, Washington MK, Lee S... [More Details]
Journal Fung S, Gordon SC, Krastev Z, Horban A, Petersen J... [More Details]
Journal Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gure... [More Details]
Journal Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Kr... [More Details]
Journal Corsa A, Liu Y, Flaherty JF, Marcellin P, Miller M... [More Details]
Journal Marcellin P, Gane EJ, Flisiak R, Trinh HN, Peterse... [More Details]
Journal Gane EJ, Marcellin P, Sievert W, Trinh HN, Shiffma... [More Details]
Journal Liu Y, Corsa AC, Buti M, Cathcart AL, Flaherty JF,... [More Details]

Results are available at https://clinicaltrials.gov/study/NCT00117676